Therapeutic Human Polyclonals Inc.

Therapeutic Human Polyclonals Inc., a California-based biopharmaceutical company with a subsidiary in Germany, has developed a unique transgenic mammalian platform to create human antibodies. THP is the first company to create transgenic rabbits with a human antibody repertoire for producing both monoclonal and polyclonal antibody therapeutics.

Working with the founders, Roland Buelow, Ph.D., and Wim Van Schooten, Ph.D., RCT provided the initial funding and incubation to develop and commercialize THP's next-generation human antibody therapies. In November 2002, SangStat Medical Corp. (acquired by Genzyme Corporation in Cambridge, Mass.) joined RCT in continuing to fund development of THP's novel antibody platform.

Roche, the world's largest biotechnology company, acquired THP for $56.5 million in April 2007. The acquisition strengthens Roche's expertise in therapeutic antibody research. The company is a global leader in therapeutic antibodies with its cancer therapies MabTheraŽ, HerceptinŽ and AvastinŽ. Roche plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research organization in Penzberg, Germany.

Inventors/Founders

Roland Buelow, Ph.D., Wim van Schooten, Ph.D.

RCT Contacts

Shaun A. Kirkpatrick, RCT President & CEO or
Jan McCoy Hutchinson, RCT Communications

Related Web Sites

Therapeutic Human Polyclonals Inc.